Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

• Status: Completed
• Trial end date: 2003-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Quetiapine Fumarate

Criteria

Inclusion Criteria:

• Written Informed Consent;

• Bipolar disorder with most recent episode depressed;

• Outpatient status

Exclusion Criteria:

• Patients with a current Axis I disorder other than bipolar disorder within 6 months of screening;

• Patients whose current episode of depression exceeds 12 months or is less than 4 weeks